ClinicaliQ Trial Snapshot
- A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists — Recruiting • Phase III • Cardiology / Cardiovascular • NCT06033950.
- What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) versus placebo in patients with heart failure and reduced ejection fraction (HFrEF) to evaluate its clinical efficacy and safety.
- Patient eligibility overview: Adults with HFrEF who cannot tolerate or are ineligible for standard steroidal mineralocorticoid receptor antagonists (sMRAs) such as spironolactone or eplerenone due to contraindications, adverse effects, or intolerance.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Eligibility Snapshot
- : * Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations * Age ≥18 years or legal age of majority if >18 years in the participant's country of residence * Symptomatic HFrEF per protocol defined criteria * Not on sMRA due to history of intolerance, contraindication, or ineligibility for treatment * Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.